IBRX270115C00005000
IBRX Jan 15 2027 5.00 Call
optionOPRA
EODOct 19, 2026
3.70USD-15.909%(-0.70)58Vol26,571OI
Loading…
Underlying
Underlying Price
$8.69
Type
Call
Strike
5
Expiration
Jan 15, 2027
DTE
87d
Moneyness
ITM
Intrinsic
$3.69
IBRX 5 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $3.65 | -28.43% | 3 | 3 |
| Oct 30, 2026 | 10d | $5.80 | +62.01% | 1 | 1 |
| Nov 6, 2026 | 17d | $4.95 | +0.00% | 2 | 1 |
| Nov 13, 2026 | 24d | $4.12 | +0.00% | 5 | 5 |
| Nov 20, 2026 | 31d | $4.85 | -6.73% | 4 | 3 |
| Nov 27, 2026 | 38d | — | — | 0 | 0 |
| Dec 18, 2026 | 59d | — | — | 0 | 0 |
| Jan 15, 2027 | 87d | $3.70 | -15.91% | 58 | 26,571 |
| Mar 19, 2027 | 150d | $5.40 | +0.93% | 15 | 350 |
| Apr 16, 2027 | 178d | $5.70 | +9.62% | 2 | 25 |
| May 21, 2027 | 213d | $4.90 | -12.19% | 5 | 60 |
| Aug 20, 2027 | 304d | $5.30 | -11.67% | 5 | 26 |
| Nov 19, 2027 | 395d | $4.55 | -13.33% | 28 | 96 |
| Jan 21, 2028 | 458d | $4.60 | -15.44% | 678 | 12,088 |
| Mar 17, 2028 | 514d | $5.90 | -3.28% | 5 | 373 |
| Jan 19, 2029 | 822d | $5.37 | -16.09% | 10 | 244 |
IBRX Nearby Strikes · Jan 15, 2027
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 2 C | $8.47 | +12.93% | 20 | 1,489 | ITM |
| 2.5 C | $6.57 | -8.11% | 13 | 5,703 | ITM |
| 3 C | $7.20 | +7.30% | 200 | 11,575 | ITM |
| 3.5 C | $6.54 | -7.23% | 4 | 4,158 | ITM |
| 4 C | $5.70 | -6.10% | 1 | 5,546 | ITM |
| 4.5 C | $5.00 | -16.94% | 1 | 2,469 | ITM |
| 5 C | $3.70 | -15.91% | 58 | 26,571 | ITM |
| 5.5 C | $3.70 | -17.78% | 22 | 7,684 | ITM |
| 7.5 C | $2.10 | -20.75% | 253 | 21,168 | ITM |
| 9 C | $1.45 | -22.46% | 123 | 6,662 | OTM |
| 10 C | $1.15 | -25.81% | 674 | 72,472 | OTM |
| 11 C | $0.90 | -21.74% | 278 | 16,211 | OTM |
| 12 C | $0.79 | -21.00% | 278 | 10,380 | OTM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.